Numaferm x Labiotech – Podcast

For the “lazy” readers amongst us, a great chance to learn more about pepteins, how they are produced at Numaferm and how we help our customers overcome existing challenges working with traditional ways of peptide and protein production.

Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides

Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics. Financial details of the deal were not disclosed.

Pepteins are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a challenge for manufacturing, yet exert a high biological activity, wherefore they play an increasing role as innovative molecules in a range of industries, including animal and human health. To date, peptein production via chemical synthesis or recombinant approaches is cumbersome, leading to time and resource-intensive development programs. This, in combination with high production costs, limits promising peptein applications. The proprietary high-titer expression platform NumaswitchTM changes this situation and enables the access to pepteins within weeks.

“We appreciate Numaferm’s expertise in the expression of therapeutic proteins and peptides, which will enhance our internal capabilities in this field,” said Robert Polzer, Executive Vice President and President, Research and Development at Zoetis. “We look forward to working together to develop innovative therapeutics to meet the needs of our customers.”

Christian Schwarz, CEO at Numaferm GmbH said: “Our mission is supporting our partners with the best-in-class peptein technologies. The partnership collaboration with Zoetis is another milestone for Numaferm, demonstrating the value of our proprietary technologies for pharma projects and beyond.”

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit

About Numaferm GmbH

Numaferm GmbH is a German biotech company based in Düsseldorf, Germany, specializing in the biochemical production of pepteins. The company offers its technology and related research and development services to partners from both pharma and non-pharma sectors. The company was publicly recognized for its pioneering work several times in media and by prestigious awards and is regarded as one of the most innovative and sustainable small and medium sized biotech companies in Europe. For more information, visit


Numaferm @ BIO International Convention, Boston

Our CEO, Dr. Christian Schwarz and our Business Development Manager, Liv Kaser are looking forward to attend the BIO International Convention in Boston, taking place from 5th – 8th June 2023.

Hosted by BIO.NRW, we will be exhibiting as part of the German Pavilion at booth #1335-01.

We are looking forward to meeting you there! Please get in touch to arrange a meeting and send an E-Mail to

ISO 9001:2015 Re-Certification

After the successful TÜV audit, we have been re-certified, fulfilling all requirements according to DIN EN ISO 9001:2015.

PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs

Baar (Switzerland) and Düsseldorf (Germany), 9 May 2023 – PolyPeptide, a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs), and Numaferm, a German biotech company specialized in process development and production of peptides and proteins, have signed a Preferred Partner Collaboration Agreement for peptide development and production, leveraging PolyPeptide’s cGMP manufacturing capacities, regulatory know-how and market access as well as Numaferm’s biochemical production platform and expertise in sustainable peptide manufacturing. The parties have agreed to keep the details of the agreement confidential.

Olivier Ludemann-Hombourger, Director Global Innovation and Technology at PolyPeptide, commented: “We are impressed by Numaferm’s track record, expertise, and their innovative biochemical production platform for next-level biosynthesis peptide manufacturing. It complements our Green Chemistry initiatives and allows us to broaden the scope of our manufacturing offering. We look forward to exploring the development of suitable peptide candidates together.”

Christian Schwarz, CEO at Numaferm, commented: “Our mission is to support our partners with best-in-class peptide and protein manufacturing technologies, covering the entire value chain. The collaboration with PolyPeptide is a major milestone giving our clients a clear route to clinical trial and commercial materials and access to industry-leading regulatory expertise. This collaboration underscores the value of our proprietary biosynthesis platform for the peptide industry.”

About PolyPeptide PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and
services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit

@PolyPeptide – follow the company on LinkedIn

About Numaferm
Numaferm GmbH is a German biotech company based in Düsseldorf, Germany, specialized in the biochemical production of peptides and proteins by proprietary technologies and products covered by more than 50 patents globally. It offers research, development and manufacturing services and enabling products for pharma and non-pharma sectors, including Fortune 500, TOP 10 Pharma and other world-leading peer companies. Numaferm’s resource-saving technologies and processes were recognized by the first Umweltwirtschaftspreis.NRW in 2020. For more information, please visit

@Numaferm – follow the company on LinkedIn

Contact PolyPeptide
Michael Stäheli
Head of Investor Relations & Corporate Communications
T: +41 43 502 0580

Contact Numaferm
Christopher Klein
CFO, Managing Director, Head IR
T: +49 151 1061 7089

This media release has been prepared jointly by PolyPeptide Group AG and Numaferm GmbH and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. The companies are providing the information in this release as of this date and, except as required by applicable laws or regulations, do not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Biologics UK – London

Dr. Christian Schwarz and Liv Kaser will be attending the Biologics UK conference in London. The conference will take place from 30. – 31. March.
Presenting our biochemical production platform Numaswitch, we are sharing case studies showing the application of our technology for peptides, pepteins and proteins.
If you would like to schedule a meeting with us, please send an E-Mail to or send us a meesage through the contact form.